查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1401844

到 2030 年无菌注射剂市场预测：按药物类型、分子类型、途径、给药配销通路、应用和地区进行的全球分析

Sterile Injectable Market Forecasts to 2030 - Global Analysis By Drug Type, Molecule Type, Route of Administration, Distribution Channel, Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球无菌注射剂市场规模为 621 亿美元，预计在预测期内复合年增长率为 9.2%，到 2030 年将达到 1,150 亿美元。

需要去除活细菌（例如细菌或真菌）的静脉注射药物称为无菌注射剂。这些注射剂可以静脉注射（IV）、给药（IM）或给药（SC）。这些注射剂设计用于直接注射到循环系统或其他无菌身体组织中。它通常在严格的无菌加工条件下製备，以确保成品不受微生物污染。

根据美国国家卫生委员会的数据，2016 年，慢性病影响了约 1.33 亿美国人，占全国总人口的 40% 以上。到 2020 年，这一数字预计将增加到约 1.57 亿，其中 8,100 万人患有多种疾病。

对无菌注射剂的偏好日益增加

药品、生物製药和疫苗等无菌注射剂对于医疗保健至关重要，特别是对于疾病管理和紧急应变。医学研究的进步导致了新的注射治疗方法的发现和发展。这包括新的医疗干预措施，例如基因疗法和细胞疗法。这些方面将在整个预测期内推动市场成长。

污染风险

儘管尽可能保持无菌，但在製造、包装和给药过程中仍可能发生污染。对患者来说，污染物会导致严重的健康问题。此外，有些注射药物需要特殊的储存条件，例如冷藏，以保持稳定性。运输和储存方面的额外物流障碍限制了市场的成长，特别是在缺乏合适设施的地区。

提高生物利用度

无菌注射剂通常比口服药物具有更好的生物利用度，因为它们不易受到胃肠道吸收不可预测性的影响。注射药物通常比口服药物起效更快。对于治疗窗有限或需要固定给药才能获得最佳效果的药物来说，注射剂是有益的，因为可以将更高浓度的药物直接输送到循环中。预计这些因素将在预期期间推动市场扩张。

包装问题

无菌注射剂包装对于维持产品完整性至关重要。包装缺陷会导致污染和药物功效降低。此外，无菌注射剂的製造和品质保证程序可能昂贵且复杂。对人们、卫生系统和製药公司来说，这代价高昂。因此，这些事情都阻碍了市场的扩张。

COVID-19 的影响：

疫情扰乱了全球供应链，导致原料、原料药成分和包装材料短缺。这影响了无菌注射剂的分销和製造。由于劳动力限制、社交距离措施和封锁，製造业活动受到干扰。劳动力短缺和旅行限制使一些製药公司难以维持生产水准。

胰岛素细分市场预计将成为预测期内最大的市场

预计胰岛素领域在预测期内将是最大的。无菌注射胰岛素对于糖尿病管理至关重要。透过协助血糖调节，它有助于避免低血糖和高血糖。注射胰岛素可以根据患者的特定要求、生活方式和血糖值精确且独特地调整给药。不同类型的胰岛素有不同的给药时间和给药，以客製化治疗。

预计癌症产业在预测期内将经历最高的复合年增长率。

预计癌症产业在预测期内将经历最高的复合年增长率。药物治疗可以透过无菌注射剂以精确和受控的方式进行。这很重要，因为癌症治疗需要精确的给药，以最大限度地提高治疗效果并减少副作用。这在癌症治疗中尤其重要，因为可能需要迅速采取行动来阻止癌细胞的生长和扩散。

占有率最大的地区

由于人口中慢性病和残疾的盛行率不断上升，预计北美在预测期内将占据最大的市场占有率。该地区发达的医疗基础设施、知名企业、有吸引力的报销规则以及在肿瘤学领域的广泛应用是推动这一市场扩张的因素。此外，美国食品药物管理局(FDA) 等监管机构对于确保该地区无菌注射药物的安全性和品质至关重要。

复合年增长率最高的地区：

由于人口中癌症患者数量不断增加以及政府加强医疗保健部门的投资大幅增加，预计亚太地区在预测期内将保持最高的复合年增长率。在医疗环境中，无菌注射剂对于实施各种治疗至关重要，包括特殊药物、疫苗接种和抗生素。大型製药企业经常在该地区生产和销售无菌注射药物。

免费客製化服务：

订阅此报告的客户可以利用以下免费自订选项之一：

  • 公司简介
    • 其他市场参与企业的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计/预测/复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 介绍
  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 应用分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球无菌注射剂市场：依药物类型

  • 介绍
  • 细胞激素
  • 单株抗体
  • 胰岛素
  • 胜肽激素
  • 血液因素
  • 疫苗
  • 免疫球蛋白
  • 胜肽抗生素
  • 其他类型的药物

第六章全球无菌注射剂市场：依分子类型

  • 介绍
  • 高分子
  • 低分子

第七章全球无菌注射剂市场：依给药途径

  • 介绍
  • 静脉注射(IV)
  • 给药（IM）
  • 给药（SC）

第八章全球无菌注射剂市场：依配销通路

  • 介绍
  • 医院药房
  • 零售药房
  • 线上药房

第九章全球无菌注射剂市场：依应用分类

  • 介绍
  • 心血管疾病
  • 肌肉骨骼系统
  • 癌症
  • 感染疾病
  • 糖尿病
  • 中枢神经系统
  • 其他用途

第十章全球无菌注射剂市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 中东和非洲其他地区

第十一章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司简介

  • Novartis AG
  • Baxter International Inc.
  • Merck & Co., Inc
  • AstraZeneca plc
  • Johnson & Johnson Services, Inc
  • Gilead Sciences, Inc.
  • JHP Pharmaceuticals
  • Pfizer Inc.
  • Fresenius Kabi Ag
  • CordenPharma
  • Hikma Pharmaceuticals PLC
  • Bryllon LLC
  • Aenova Holding GmbH
  • Vetter Pharma-Fertigung GmbH & Co. KG
  • Catalent Pharma Solutions
Product Code: SMRC24364

According to Stratistics MRC, the Global Sterile Injectable Market is accounted for $62.1 billion in 2023 and is expected to reach $115.0 billion by 2030 growing at a CAGR of 9.2% during the forecast period. Pharmaceuticals that are given intravenously and must be devoid of live germs like bacteria or fungus are referred to as sterile injectables. These injectables can be given intravenously (IV), intramuscularly (IM), or subcutaneously (SC). They are designed to be directly injected into the circulation or other sterile bodily tissues. To guarantee that there is no microbiological contamination in the finished product, they are usually prepared under stringent aseptic processing conditions.

According to the National Health Council, in 2016, chronic diseases affect approximately 133 million Americans, representing more than 40% of the total population of the country. By 2020, that number is projected to grow to an estimated 157 million, with 81 million having multiple conditions.

Market Dynamics:

Driver:

Rise in inclination towards sterile injectables

Sterile injectables, such as medicines, biologics, and vaccinations, are essential to healthcare, particularly for managing diseases and in emergency circumstances. New treatment methods, many of which are injected, have been discovered and developed as a result of advancements in medical research. This covers novel medical interventions such as gene and cell therapy. These are the aspects driving market growth throughout the predicted period.

Restraint:

Risk of contamination

Although sterility is maintained to the best of our ability, contamination can still occur during production, packing, or administration. For patients, contaminants can result in major health problems. Additionally, in order to preserve stability, some injectable medications may need special storage conditions, such refrigeration. Creating additional logistical hurdles for transportation and storage, particularly in areas with poor access to adequate facilities restrains the market growth.

Opportunity:

Increased bioavailability

Sterile injectables frequently offer better bioavailability than oral drugs because they are not susceptible to the unpredictability of gastrointestinal absorption. Medications that are injectable frequently start working faster than those that are oral. For drugs with a limited therapeutic window or those needing a certain dosage for best efficacy, they are beneficial since they deliver larger drug concentrations straight into the circulation. During the anticipated time, these factors will be propelling market expansion.

Threat:

Packaging concerns

Sterilized injectable packaging is essential to preserving the integrity of the product. A breach in the package may result in contamination or a reduction in the medication's effectiveness. Furthermore, the production and quality assurance procedures for sterile injectables can be expensive and complicated. Higher expenses follow for people, healthcare systems, and pharmaceutical corporations alike. Thus, these are the things impeding the market's expansion.

COVID-19 Impact:

The pandemic caused supply chain disruptions on a worldwide scale, resulting in shortages of raw materials, active pharmaceutical ingredients (APIs), and packaging supplies. This has an impact on the distribution and manufacturing of sterile injectables. Manufacturing activities were disrupted by personnel constraints, social distancing measures, and lockdowns. Due to workforce shortages and mobility constraints, several pharmaceutical businesses found it difficult to sustain production levels.

The insulin segment is expected to be the largest during the forecast period

The insulin segment is expected to be the largest during the forecast period. Insulin that is sterile for injection is an essential part of managing diabetes. By assisting in blood glucose regulation, it helps avoid hypo- and hyperglycemia. With injectable insulin, dosage may be precisely and uniquely adjusted for each patient depending on their unique requirements, lifestyle, and blood glucose levels. To customize therapy, a variety of insulin types with different onset and duration characteristics are available.

The cancer segment is expected to have the highest CAGR during the forecast period

The cancer segment is expected to have the highest CAGR during the forecast period. Medication may be administered precisely and under control to sterile injectables. This is important because, in the treatment of cancer, precise dosage is necessary to maximize therapeutic efficacy and reduce adverse effects. This can be especially crucial for cancer therapy, as it may be required to act quickly to stop the growth and spread of cancer cells.

Region with largest share:

North America is projected to hold the largest market share during the forecast period due to the rise in prevalence of chronic diseases and disorders among population. The region's well-developed healthcare infrastructure, well-known companies, attractive reimbursement rules, and strong use in the cancer sector are all credited with this expansion. Furthermore, regulating organizations like the Food and Drug Administration (FDA) of the United States are essential in guaranteeing the security and caliber of sterile injectable medications in the area.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period due to the increasing prevalence of cancer cases among people and surging investment by government with the purpose of enhancing healthcare sector. In healthcare settings, sterile injectables are essential for administering a range of treatments, such as specialized medications, vaccinations, and antibiotics. Sterile injectable medications are often manufactured and distributed in the region by major pharmaceutical businesses, both domestic and foreign.

Key players in the market:

Some of the key players in Sterile Injectable market include Novartis AG, Baxter International Inc., Merck & Co., Inc, AstraZeneca plc, Johnson & Johnson Services, Inc, Gilead Sciences, Inc., JHP Pharmaceuticals, Pfizer Inc., Fresenius Kabi Ag, CordenPharma, Hikma Pharmaceuticals PLC, Bryllon LLC, Aenova Holding GmbH, Vetter Pharma-Fertigung GmbH & Co. KG and Catalent Pharma Solutions.

Key Developments:

In November 2023, AstraZeneca announced a collaboration and investment agreement with Cellectis, a clinical-stage biotechnology company, to accelerate the development of next generation therapeutics in areas of high unmet need, including oncology, immunology and rare diseases.

In January 2022, Johnson & Johnson Medical Devices Companies announced that it will collaborate with Microsoft to further enable and expand JJMDC's secure and compliant digital surgery ecosystem.

In January 2021, Novartis announced collaboration with Alnylam to leverage Alnylam's proven, proprietary siRNA technology to inhibit a target discovered at the Novartis Institutes for BioMedical Research, potentially leading to development of a treatment designed to promote the regrowth of functional liver cells and to provide an alternative to transplantation for patients with liver failure.

Drug Types Covered:

  • Cytokines
  • Monoclonal Antibodies
  • Insulin
  • Peptide Hormones
  • Blood Factors
  • Vaccines
  • Immunoglobulins
  • Peptide Antibiotics
  • Other Drug Types

Molecule Types Covered:

  • Large Molecules
  • Small Molecules

Route of Administrations Covered:

  • Intravenous (IV)
  • Intramuscular (IM)
  • Subcutaneous (SC)

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Applications Covered:

  • Cardiovascular Diseases
  • Musculoskeletal
  • Cancer
  • Infections
  • Diabetes
  • Central Nervous Systems
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Sterile Injectable Market, By Drug Type

  • 5.1 Introduction
  • 5.2 Cytokines
  • 5.3 Monoclonal Antibodies
  • 5.4 Insulin
  • 5.5 Peptide Hormones
  • 5.6 Blood Factors
  • 5.7 Vaccines
  • 5.8 Immunoglobulins
  • 5.9 Peptide Antibiotics
  • 5.10 Other Drug Types

6 Global Sterile Injectable Market, By Molecule Type

  • 6.1 Introduction
  • 6.2 Large Molecules
  • 6.3 Small Molecules

7 Global Sterile Injectable Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Intravenous (IV)
  • 7.3 Intramuscular (IM)
  • 7.4 Subcutaneous (SC)

8 Global Sterile Injectable Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Hospital Pharmacies
  • 8.3 Retail Pharmacies
  • 8.4 Online Pharmacies

9 Global Sterile Injectable Market, By Application

  • 9.1 Introduction
  • 9.2 Cardiovascular Diseases
  • 9.3 Musculoskeletal
  • 9.4 Cancer
  • 9.5 Infections
  • 9.6 Diabetes
  • 9.7 Central Nervous Systems
  • 9.8 Other Applications

10 Global Sterile Injectable Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Novartis AG
  • 12.2 Baxter International Inc.
  • 12.3 Merck & Co., Inc
  • 12.4 AstraZeneca plc
  • 12.5 Johnson & Johnson Services, Inc
  • 12.6 Gilead Sciences, Inc.
  • 12.7 JHP Pharmaceuticals
  • 12.8 Pfizer Inc.
  • 12.9 Fresenius Kabi Ag
  • 12.10 CordenPharma
  • 12.11 Hikma Pharmaceuticals PLC
  • 12.12 Bryllon LLC
  • 12.13 Aenova Holding GmbH
  • 12.14 Vetter Pharma-Fertigung GmbH & Co. KG
  • 12.15 Catalent Pharma Solutions

List of Tables

  • Table 1 Global Sterile Injectable Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Sterile Injectable Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 3 Global Sterile Injectable Market Outlook, By Cytokines (2021-2030) ($MN)
  • Table 4 Global Sterile Injectable Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
  • Table 5 Global Sterile Injectable Market Outlook, By Insulin (2021-2030) ($MN)
  • Table 6 Global Sterile Injectable Market Outlook, By Peptide Hormones (2021-2030) ($MN)
  • Table 7 Global Sterile Injectable Market Outlook, By Blood Factors (2021-2030) ($MN)
  • Table 8 Global Sterile Injectable Market Outlook, By Vaccines (2021-2030) ($MN)
  • Table 9 Global Sterile Injectable Market Outlook, By Immunoglobulins (2021-2030) ($MN)
  • Table 10 Global Sterile Injectable Market Outlook, By Peptide Antibiotics (2021-2030) ($MN)
  • Table 11 Global Sterile Injectable Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 12 Global Sterile Injectable Market Outlook, By Molecule Type (2021-2030) ($MN)
  • Table 13 Global Sterile Injectable Market Outlook, By Large Molecules (2021-2030) ($MN)
  • Table 14 Global Sterile Injectable Market Outlook, By Small Molecules (2021-2030) ($MN)
  • Table 15 Global Sterile Injectable Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 16 Global Sterile Injectable Market Outlook, By Intravenous (IV) (2021-2030) ($MN)
  • Table 17 Global Sterile Injectable Market Outlook, By Intramuscular (IM) (2021-2030) ($MN)
  • Table 18 Global Sterile Injectable Market Outlook, By Subcutaneous (SC) (2021-2030) ($MN)
  • Table 19 Global Sterile Injectable Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 20 Global Sterile Injectable Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 21 Global Sterile Injectable Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 22 Global Sterile Injectable Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 23 Global Sterile Injectable Market Outlook, By Application (2021-2030) ($MN)
  • Table 24 Global Sterile Injectable Market Outlook, By Cardiovascular Diseases (2021-2030) ($MN)
  • Table 25 Global Sterile Injectable Market Outlook, By Musculoskeletal (2021-2030) ($MN)
  • Table 26 Global Sterile Injectable Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 27 Global Sterile Injectable Market Outlook, By Infections (2021-2030) ($MN)
  • Table 28 Global Sterile Injectable Market Outlook, By Diabetes (2021-2030) ($MN)
  • Table 29 Global Sterile Injectable Market Outlook, By Central Nervous Systems (2021-2030) ($MN)
  • Table 30 Global Sterile Injectable Market Outlook, By Other Applications (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.